Reboxetine as a potentially effective treatment for attention deficit hyperactivity disorder [1]

Journal of Child and Adolescent Psychopharmacology

Volumn 11, Issue 2, 2001, Pages 203-204

  Otka, Jessica E ^a   Mercadante, Marcos T ^a   Lawrence Scahill, M S N ^a   Leckman, James F ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE;

ADULT; ATTENTION DEFICIT DISORDER; CASE REPORT; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LETTER; MALE; PERSONALITY DISORDER; SIDE EFFECT;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; HUMANS; MALE; MORPHOLINES;

EID: 0034960525     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454601750284135     Document Type: Letter

References (8)

1. Double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy
2. Attention-deficit disorder: A review of the past ten years
3. Clinical utility of the Test of Variables of Attention (TOVA) in the diagnosis of attention-deficit/hyperactivity disorder
4. Attention-deficit disorder: The stimulants
5. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: A double-blind placebo-controlled study with clonidine and desipramine
6. Reboxetine: A pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor